Author: Penny Jefferson, MSN, RN, CCDS, CCDS-O, CCS, CDIP, CRC, CHDA, CRCR, CPHQ, ACPA-C | November 16, 2026
Throughout 2026, we discussed how documentation affects medical necessity, payer review, quality measures, and payment. As 2027 approaches, the question is whether those conversations have changed our daily work.
Over the past year, I have written about the information payers receive, the clinical reasoning behind admission decisions, the integrity of hospital benchmarks, and what happens when documentation becomes a legal question. We have also looked at sepsis, surgical episodes, advance care planning, risk adjustment, and outpatient drug billing. These may appear to be separate topics. In practice, they follow the same patient and depend on the same record.
As we prepare for 2027, I would bring those discussions back to one question: can we follow the patient’s clinical story through the decisions, data, and claims it produces – and explain where the information changes?
That is the readiness conversation I want clinical documentation integrity (CDI), coding, utilization review (UR), physician advisors, quality, compliance, revenue integrity, and clinical leaders to have together. An education session is a beginning. We also need evidence that the resulting workflow works.
Get the Calendar Right
First, separate what is already in effect, from what begins in January and what requires preparation for a future year. ICD-10 updates for the 2027 fiscal year (FY) began Oct. 1, 2026. January brings calendar-year payment and operational changes. A future payment year may depend on an earlier performance period, so each project needs its own implementation, measurement, submission, and payment dates.
The 2027 outpatient final rule removes 637 services from Medicare’s Inpatient-Only (IPO) List. That creates more outpatient payment options; it does not establish that every patient receiving one of those services belongs in outpatient status. Hospitals should compare the final list with actual surgical volume, update scheduling, and status workflows, and evaluate the financial effects using their own payer mix and contracts.
The leadership question is not “How many procedures can we move to outpatient?” It is “Can we show that each patient’s status was selected for the right clinical reason, documented at the right time, and billed under the applicable rules?” That is where CDI, UR, physician advisors, surgeons, coding, compliance, and revenue integrity must work from the same playbook.
Priority No. 5: Test the documentation and claim together. For selected removed procedures, trace the planned status, admission order, physician rationale, actual course, discharge documentation, coding, modifiers, charges, and final claim. Track short-stay denials, status changes, avoidable write-offs, and unexpected outpatient packaging or payment differences. Use the findings for targeted education, rather than treating every status variance as an error.
Priority No. 4: Payment, coverage, and authorization remain separate checks. Removal from the IPO list does not override an NCD, LCD, Medicare Advantage (MA), or commercial payer coverage rule, medical-necessity requirements, or a payer-specific authorization obligation. Nor does it establish that a service will receive separate Outpatient Prospective Payment System (OPPS) payment in every setting. Revenue integrity and contracting should validate applicable payment rules and the complete encounter, not simply compare inpatient and outpatient rates for a single procedure.
Priority No. 3: Rebuild the surgical workflow before Jan. 1. Compare the final 2027 IPO removals with the organization’s prior-year surgical volume; identify affected specialties and surgeons; and review scheduling, preauthorization, preoperative status planning, orders, patient notices, bed management, case management, and post-procedure escalation. The surgeon, anesthesia team, UR, physician advisor, perioperative leadership, coding, and revenue cycle should agree on how an unexpected complication or change in clinical condition triggers reassessment.
Priority No. 2: Do not confuse the two-midnight benchmark with a review exemption. The Centers for Medicare & Medicaid Services’ (CMS’s) medical-review policies for newly removed procedures and the physician’s obligation to support the admission decision are separate issues. UR and physician advisors should document the expected duration and intensity of care, comorbidities, surgical risk, complications, and the clinical rationale at the time of the admission decision.
Priority No. 1: A removed procedure is not automatically outpatient. Once a service is no longer on the IPO list, Medicare does not require Part A inpatient billing solely because of the procedure code. The patient may still warrant inpatient admission based on the physician’s reasonable expectation of medically necessary hospital care spanning at least two midnights, or a supported case-by-case exception. Conversely, a planned inpatient admission is not justified by historical IPO status alone.
The removal of 637 services from Medicare’s IPO List for 2027 is a payment-policy change, not a blanket determination that the procedures are clinically appropriate for outpatient care. The final list, not the proposed list or a vendor summary, must drive the hospital’s code-level analysis. This is particularly important for procedures that historically have moved through an inpatient surgical pathway. [2]
UR and physician advisors should also distinguish the applicable two-midnight policy from exemptions from certain medical-review activities. An exemption from specified review activity should not become a reason to stop documenting the patient-specific admission decision. Operational priorities for hospitals in 2027 should include the following:
Move the Review to the Decision
My articles on medical necessity and the payer review process repeatedly returned to the front door. Does the emergency department record, admission order, and history and physical explain why this patient needed this level of care at that time?
Before January, I would review a sample of short stays and surgical admissions with CDI, UR, and physician advisors. Look for the physician’s anticipated course, clinical risk, treatment needs, and explanation when a shorter inpatient stay is appropriate. CMS emphasizes the importance of that individualized rationale for case-by-case exceptions.
Then examine the handoff. Who notices a gap? Who contacts the treating practitioner? Where is the clarification documented? What happens overnight, or on weekends? A strong process needs a clear route from identifying a concern to resolving it.
Know which Coverage Question You Are Answering
A procedure’s payment status, its medical necessity, its authorization requirements, and the documentation supporting its diagnosis are different questions. Our readiness work should keep them distinct.
For high-volume and high-risk services, verify the applicable National Coverage Determination (NCD), Local Coverage Determination (LCD), associated billing instructions, and payer requirements for the date of service. National and local policies operate at different levels; local coverage can vary by Medicare contractor jurisdiction. Multistate organizations should not assume that one location’s instructions apply everywhere.
My earlier discussion of prior authorization reductions also raised an operational question worth carrying forward: when a requirement changes, have we updated the correct plan and code combinations? Track the effect through payment, including medical necessity denials and retrospective reviews, rather than measuring only fewer authorization requests.
Test the Information Leaving the EHR
Under CMS-0057-F, payer application programming interface (API) requirements generally begin in 2027, with exact compliance dates varying by payer type. The rule also introduces an electronic prior authorization measure for eligible hospitals and critical access hospitals (CAHs), beginning with the 2027 electronic health record (EHR) reporting period. These are distinct responsibilities, and organizations should verify their applicable specifications and exclusions.
That makes interoperability a clinical and revenue cycle concern, as well as an IT project. Ask what information the workflow sends, whether it reflects the current encounter, and how incomplete requests, denials, and requests for additional information return to the team responsible for acting on them.
A successful connection does not prove that the clinical content is accurate. I would test representative cases from the source documentation to the information actually transmitted. Old problem-list entries, conflicting diagnoses, and incomplete admission narratives deserve attention before they are reused downstream.
Protect Clinical Validation from Performance Pressure
Recent articles on hospital benchmarking, U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) audits, and documentation governance asked a difficult question: what happens when correcting the record makes a performance number less favorable?
Our 2027 plan should give equal attention to supported diagnoses that are missing and documented diagnoses that need clarification. Reporting criteria and clinical validation address different issues. Coders should follow official guidance while unresolved clinical concerns move through an established clarification and escalation process.
That includes how we review sepsis, malnutrition, respiratory failure, and disputed wound diagnoses. A desired Diagnosis-Related Group (DRG), risk score, or quality result should not determine the clinical conclusion. Audit automated prompts and artificial intelligence (AI)-assisted recommendations for the evidence presented, the clinician’s response, and the resolution of conflicting information. My recommendation is to measure accuracy and corrective follow-through alongside productivity and financial impact.
Understand the Populations behind Quality Measures
Our sepsis discussions highlighted how different methods can identify different patients. Claims, clinical surveillance, and quality specifications do not necessarily produce identical populations. Before comparing results, teams should be able to explain the definition, exclusions, timing, and data source behind each number.
CMS finalized sepsis readmission early-look reports for FY 2028 and FY 2029, with payment-reduction calculations beginning in FY 2030. The FY 2027 rule also adopted modified mortality measures incorporating MA patients beginning with the FY 2028 Inpatient Quality Reporting (IQR) payment determination, with modified measures entering Hospital Value-Based Purchasing (VBP) in FY 2032. These are preparation priorities, not new January 2027 penalties.
For failure to rescue, patient safety indicators, and external rankings, I would ask quality and analytics to demonstrate how the applicable specifications use diagnoses, complications, and present-on-admission (POA) information. Review the record for accuracy, then evaluate its measure effect. Improving a benchmark should never substitute for understanding what happened to the patient.
Advance care planning belongs here, too. CMS finalized its electronic Clinical Quality Measure (eCQM) for the FY 2030 payment determination. Use the preparation period to reconcile patient preferences, surrogate information, orders, narrative notes, and structured fields. The information must remain useful to the next care team, as well as available for measurement.
Follow Surgical Patients beyond Discharge
The Transforming Episode Accountability Model (TEAM) is already operating for selected hospitals and continues through 2030, with episodes extending 30 days after discharge. Participation is not universal. Hospitals included in the model should verify their 2027 track, financial exposure, target-price information, and current specifications.
Comprehensive Care for Joint Replacement Expanded (CJR-X) begins Jan. 1, 2028, with 90-day episodes. Unlike TEAM, CJR-X is mandatory nationwide for most eligible acute-care hospitals, subject to exclusions, including TEAM participants, Maryland hospitals, and hospitals not eligible for both Inpatient Prospective Payment System (IPPS) and OPPS payment. For affected organizations, 2027 is a preparation year.
Both discussions bring outpatient CDI, surgical clinics, case management, rehabilitation, and post-acute partners into the same room. Review how baseline complexity, surgical indications, complications, discharge needs, and follow-up plans travel across settings. A completed inpatient claim does not complete the patient’s episode.
Check the Models Affecting Ambulatory Care and Payment
The Ambulatory Specialty Model (ASM) belongs on the immediate readiness list. It applies to selected specialists treating heart failure or lower back pain, with performance beginning Jan. 1, 2027. Selection occurs at the taxpayer identification number and National Provider Identifier (NPI) combination, so hospital leaders should verify whether their employed and affiliated clinicians are selected participants, rather than assuming universal applicability. Payment adjustments follow performance by two calendar years. Outpatient CDI, specialty leadership, coding, quality, and analytics should verify diagnosis accuracy, episode attribution, care coordination, and reporting workflows before the performance year starts.
Other models require an applicability check. ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) is a voluntary model for eligible participants and ties payment to outcomes in technology-supported chronic care. For participating organizations and referring practices, I would review how baseline status, follow-up outcomes, electronic updates, and any billed co-management work are documented.
LEAD (the Long-term Enhanced ACO Design Model) is a voluntary Accountable Care Organization (ACO) model beginning Jan. 1, 2027, following ACO REACH (Accountable Care Organization Realizing Equity, Access, and Community Health). Organizations entering LEAD should confirm participation arrangements, attribution, risk-adjustment data quality, and responsibility for care transitions with their population health and contracting teams. Neither model creates a universal hospital participation requirement.
For readers in participating states or regions, AHEAD (Achieving Healthcare Efficiency through Accountable Design) also warrants leadership review. Its hospital global budgets and total-cost-of-care approach make coordination between finance, quality, clinical leaders, and documentation teams essential. Confirm the applicable state, cohort, participation pathway, and implementation calendar before assigning deadlines.
GLOBE (Global Benchmark for Efficient Drug Pricing Model) connects directly to our outpatient drug billing discussion. The model begins Jan. 1, 2027; reduced coinsurance for selected eligible beneficiaries and drugs begins April 1, 2027. Participation is mandatory for manufacturers of qualifying Part B drugs, not for hospitals as model participants. Hospitals and suppliers serving selected beneficiaries should validate remittance and patient-liability workflows; CMS states that no separate GLOBE billing system or modifier is required.
For every applicable model, the first deliverable should be a named operational owner and a documented assessment of what changes in the clinical record, data submission, or payment workflow. A model announcement becomes actionable when someone can explain which patients and clinicians it affects, and what must work differently.
Check the Claims that Were Paid
My outpatient drug billing segment asked who verifies that the claim accurately represents the medication administered. In its October 2026 data brief, HHS OIG identified 160,918 Medicare Part B outpatient drug claim lines, spanning dates of service from April 1, 2024, through March 31, 2025, where billed procedure codes did not match codes associated with the reported drug identifiers in CMS crosswalk files. OIG described potential oversight vulnerabilities, including absent system edits and gaps in provider education. These mismatches warrant investigation; the full set of claim lines should not be described as confirmed improper payments.
Carry that question into 2027 system testing. Follow selected medications from product identification and administration through charge mapping, HCPCS assignment, billing units, and the final claim. Include applicable discarded-drug reporting and modifiers in the review. Pharmacy, revenue integrity, coding, billing, and informatics need a shared way to resolve discrepancies. A documentation query cannot repair an incorrect system conversion.
Use the Program for Evaluating Payment Patterns Electronic Report (PEPPER), audit findings, and denial patterns to select additional areas for review. PEPPER identifies patterns warranting attention, not proof of payment errors. The useful outcome is a tested correction and evidence that the problem stopped recurring.
California: An Additional Layer of AI Oversight for 2027
For California organizations, federal readiness is only part of the conversation. State requirements create an additional governance checkpoint for AI used in patient care and coverage decisions. Three laws should be considered together, but not treated as interchangeable: SB 1120, already effective Jan. 1, 2025, and AB 1979 and SB 503, both taking effect Jan. 1, 2027.
SB 1120 addresses the use of AI, algorithms, and other software in utilization review and utilization management. Its safeguards focus on individualized clinical information, and prohibit an AI tool from replacing a licensed professional’s determination of medical necessity or other clinical decisions within the law’s scope. For UR, physician advisors, and denials teams, the question is not simply whether an automated recommendation was generated, but whether the decision and its rationale meet the applicable requirements.
AB 1979 focuses on preserving licensed clinicians’ independent professional judgment when covered healthcare entities use AI clinical decision-support tools. It also restricts AI from independently undertaking functions that require a professional license. SB 503 separately addresses known or reasonably foreseeable discriminatory impacts of covered clinical decision-support systems, with responsibilities that differ for developers and deployers. These laws are not a blanket prohibition on AI, and their precise application depends on the statutory definitions and the role of the organization.
What should California hospitals do before January? Start with a cross-functional inventory: which tools influence clinical decisions, which support utilization review, which merely assist documentation, and which are subject to each statute? Then identify the licensed decision-makers, review and override pathways, validation, and bias-assessment processes, vendor responsibilities, and the record retained when an AI-generated recommendation is accepted, modified, or rejected. CDI and coding should be part of that review when generated diagnoses, queries, or summaries could influence the clinical record; compliance, informatics, quality, UR, and physician leadership should own the controls appropriate to their workflows.
The practical test is whether the organization can demonstrate who made the clinical decision, what patient-specific information informed it, and how unsupported or biased recommendations are detected and corrected. AI may accelerate the workflow; it should not obscure accountability.
Give the Work an Owner
Before the year ends, I would ask each team to bring its highest-priority unresolved issue to a shared readiness meeting. Identify the affected patients and services, the responsible owner, the applicable date, the workflow change, and how completion will be verified. Keep clinical education, EHR testing, policy updates, and audit follow-up connected.
We have spent the year discussing why documentation matters across the organization. Now we need to show what we did with that information. When the first patient arrives in 2027, the test will be whether the people, processes, and systems associated with that patient can produce a clear, accurate, and defensible record.
2027 Readiness at a Glance
Companion Planning Guide | Distinguish compliance dates from preparation priorities.
TimingPriorityAccountability and next stepAlready effectiveFY 2027 ICD-10 updates: Oct. 1, 2026.Coding/CDI: confirm code-set implementation, education, and post-update review.Jan. 1, 2027637 services removed from the IPO List.UR, surgeons, PAs, revenue cycle: validate affected volume, status workflows, coverage, and payment modeling.Generally, 2027; payer-specific datesCMS-0057-F API requirements; hospital electronic prior authorization measure begins with CY 2027 reporting.IT, access, UM, and PI reporting lead: confirm applicability, test requests and responses, and review measure exclusions.2027 performance yearTEAM continues; applicable tracks and financial exposure need review.Episode lead, finance, surgery, CDI, and case management: verify current specifications and care-transition processes.Prepare during 2027 for 2028CJR-X begins Jan. 1, 2028; verify participation and exemptions.Executive sponsor and episode team: plan documentation, analytics, post-acute coordination, and 90-day episode oversight.FY 2028–2029 early look; FY 2030 paymentSepsis readmission measure.Quality, CDI, coding, and analytics: reconcile cohorts and plan review of confidential reports.FY 2028 IQR; FY 2032 VBPModified mortality measures include MA patients.Quality/Analytics: distinguish program years and underlying performance periods.FY 2030 payment determinationAdvance Care Planning eCQM.Quality, informatics, clinical teams, and health information management (HIM): verify measurement dates and structured-data capture.Ongoing readiness workClinical validation, query/AI governance, coverage policies, paid-claim testing, and audit follow-through.Assign an owner, evidence of completion, and recheck date for each identified gap.Jan. 1, 2027California AB 1979 and SB 503: clinical AI oversight and biased-impact safeguards.Compliance, clinical leadership, CDI, quality, and informatics: inventory covered tools, confirm independent clinical judgment, assess bias risks, and document oversight.
Models: Confirm Applicability before Assigning Work
TEAM, CJR-X, and ASM merit a direct participation check. The remaining models need targeted review based on organizational participation, geography, or affected services.
ModelWho needs to actReadiness focusTEAMSelected hospitals; already active.Verify 2027 track, financial risk, target prices, and 30-day episode coordination.CJR-XApplicable hospitals; starts January 2028.Use 2027 for 90-day episode preparation. Verify exclusions, including TEAM participation.ASMSelected specialists; January 2027 performance start.Check TIN/NPI participation. Validate outpatient documentation, attribution, and quality reporting; payment adjustments lag two years.ACCESSVoluntary participants and referring/co-managing practices.Validate baseline and outcome data, patient updates, and support for any co-management billing.LEADVoluntary ACO participants; starts January 2027.Confirm organizational participation and attribution, risk-adjustment, and care-transition responsibilities.AHEADParticipating states/regions and organizations.Verify cohort-specific timing and hospital/global-budget or other participation pathway with Finance and population health.GLOBEManufacturers participate; affected providers assess billing implications.January 2027 launch; applicable coinsurance changes begin April 2027. Check affected drugs, beneficiaries, and system updates.
2027–2030 Impact and Participation Matrix
“Mandatory” means required only for organizations, clinicians, payers, or manufacturers meeting the stated applicability criteria. “Voluntary” identifies optional model participation; “operational review” is a recommended internal action, not a separate legal mandate. Years distinguish effective dates, model performance periods, and later quality-payment consequences.
TopicImpact yearMandatory vs. voluntary / scopeWho should participateFY 2027 ICD-10-CM/PCS and IPPSOctober 2026 / FY 2027Mandatory coding/payment rules for applicable hospitalsHIM coding, CDI, compliance, finance, IT; physician advisorsCY 2027 OPPS; 637 IPO List removalsJanuary 2027Mandatory payment rules for applicable services; inpatient status remains individualizedUR, physician advisors, surgery, coding, CDI, revenue integrity, financeTwo-Midnight and NCD/LCD coverageOngoing; reassess 2027Mandatory where Medicare coverage/payment rules apply; payer-specific variationUR, physician advisors, compliance, coding, revenue cycle, cliniciansCMS-0057-F payer APIs/ePA reporting2026 operational provisions; 2027 API/measure milestonesMandatory for specified impacted payers and eligible reporting entities; not all providers have identical dutiesIT/EHR, patient access, UR, revenue cycle, compliance, payer relationsClinical validation/AI-assisted CDIOngoing; 2027 readinessMandatory underlying coding, record and privacy duties; AI prompt audits recommendedCDI, coding, medical staff, compliance, quality, IT/AI governanceSepsis HRRP readmissionsFY 2028–29 early look; FY 2030 paymentMandatory HRRP measure for applicable hospitals; review now recommendedQuality, CDI, sepsis leads, analytics, case management, financeMA-inclusive mortality measuresFY 2028 payment determinationMandatory IQR specifications for applicable hospitalsQuality, CDI, coding, analytics, clinical service linesAdvance Care Planning eCQMFY 2030 payment determinationMandatory reporting for applicable IQR hospitals under final-rule scheduleQuality, IT/EHR, nursing, physicians, HIM, complianceTEAM2026–2030Mandatory selected hospitals; limited voluntary opt-in pathwaysFinance, quality, CDI, coding, surgery, case management, post-acuteCJR-XJanuary 2028Mandatory nationwide for most eligible acute-care hospitals; exclusions applyOrthopedics, finance, CDI, coding, quality, UR, post-acuteAmbulatory Specialty Model (ASM)January 2027Mandatory for selected specialists/TIN–NPI combinationsSpecialty clinicians, OP CDI, quality, analytics, finance, ITACCESS2026 onward/model scheduleVoluntary for eligible participantsAmbulatory leadership, digital health, finance, quality, complianceAHEADState-specific implementation yearsVoluntary state participation; obligations for participating entitiesState strategy, C-suite, finance, quality, population health, CDILEADModel-specific future timelineParticipation/applicability check; do not assume mandatory hospital enrollmentACO/population health, finance, quality, analytics, complianceGLOBE Part B drug modelJanuary 2027; coinsurance April 2027Mandatory qualifying manufacturers; provider operational impact where applicablePharmacy, revenue integrity, billing, finance, patient financial servicesOIG outpatient drug coding findings2026 report; remediation in 2027Audit recommendation; underlying claim accuracy requirements mandatoryPharmacy, revenue integrity, chargemaster, coding, complianceCalifornia SB 1120 AI in URJanuary 2025; ongoingMandatory for covered California utilization-review decisionsUR, physician advisors, compliance/legal, payer contracting, AI governanceCalifornia AB 1979 clinical AIJanuary 2027Mandatory for covered entities and covered AI usesCMO, clinicians, compliance/legal, IT, AI governance, CDICalifornia SB 503 AI bias safeguardsJanuary 2027Mandatory for covered developers/deployers as specified by statuteCompliance/Legal, AI governance, IT/vendors, quality, equity leadersPEPPER and denial trend reviewsOngoing; 2027 planningVoluntary analytic improvement activity; not itself a CMS compliance mandateCDI, coding, revenue cycle, denials, compliance, analytics
References
Primary-source verification updated Nov. 16, 2026. Model participation and applicability must be confirmed for each organization.
1. CMS. ICD-10 files and FY 2027 Official Guidelines.
2. CMS. CY 2027 OPPS/ASC Final Rule fact sheet. November 4, 2026.
3. CMS. Two-Midnight Rule Fact Sheet.
4. CMS. Hospital Patient Status Review Frequently Asked Questions.
5. CMS. Medicare Coverage Determination Process.
6. CMS. Interoperability and Prior Authorization Final Rule CMS-0057-F.
7. ACDIS. Clinical validation and the role of the CDI professional (2021 update).
8. CMS. FY 2027 IPPS/LTCH PPS Final Rule fact sheet. July 31, 2026.
9. CMS. Transforming Episode Accountability Model.
10. CMS. Comprehensive Care for Joint Replacement Expanded Model. https://www.cms.gov/priorities/innovation/innovation-models/cjr-x
11. HHS OIG. Potential Vulnerabilities in CMS’s Oversight of Medicare Providers’ Billing of Selected Outpatient Drugs. OAS-25-09-090, October 2026. https://www.oig.hhs.gov/reports/all/2026/potential-vulnerabilities-in-cmss-oversight-of-medicare-providers-billing-of-selected-outpatient-drugs/
12. PEPPER. Frequently Asked Questions.
13. CMS. Ambulatory Specialty Model: CY 2027 PFS Final Rule Fact Sheet.
14. CMS. Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model.
15. CMS. Long-term Enhanced ACO Design (LEAD) Model.
16. CMS. Achieving Healthcare Efficiency through Accountable Design (AHEAD) Model.
17. CMS. Global Benchmark for Efficient Drug Pricing (GLOBE) Model. https://www.cms.gov/priorities/innovation/innovation-models/globe
18. California Assembly Bill 1979 (2026), Chapter 854, Health care services: artificial intelligence. Effective January 1, 2027. https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202520260AB1979
19. California Senate Bill 503 (2026), Chapter 857, clinical decision-support systems and biased impacts. Effective January 1, 2027. https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202520260SB503 20. California Senate Bill 1120 (2024), Physicians and surgeons: artificial intelligence, effective January 1, 2025. https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240SB1120
This article was originally published on RACmonitor.